MoneyWorks4Me

RPG Life Sciences - Quaterly Results

17 Oct 2022 Evaluate
The Revenue for the quarter ended  September 2022 of Rs. 1347.90 millions grew by 19.65 % from Rs. 1126.50 millions.Good  Net Profit growth of 26.79% reported above the corresponding previous quarter figure of Rs. 157.50 millions to Rs. 199.70 millioins.Operating profit surged to 309.60 millions from the corresponding previous quarter of 265.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1347.90 1126.50 19.65 2637.20 2207.80 19.45 4401.60 3891.40 13.11
Other Income 12.30 7.10 73.24 24.50 11.20 118.75 29.90 9.10 228.57
PBIDT 309.60 265.10 16.79 600.20 498.70 20.35 893.50 708.40 26.13
Interest 0.80 1.70 -52.94 1.90 3.00 -36.67 5.20 7.90 -34.18
PBDT 308.80 263.40 17.24 598.30 495.70 20.70 888.30 700.50 26.81
Depreciation 38.70 39.90 -3.01 77.00 79.50 -3.14 156.60 164.70 -4.92
PBT 270.10 223.50 20.85 521.30 416.20 25.25 731.70 535.80 36.56
TAX 70.40 66.00 6.67 139.50 122.90 13.51 216.90 135.80 59.72
Deferred Tax -1.20 -1.00 20.00 2.10 -1.90 -210.53 -10.70 -35.70 -70.03
PAT 199.70 157.50 26.79 381.80 293.30 30.17 514.80 400.00 28.70
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 22.97 23.53 -2.40 22.76 22.59 0.76 20.30 18.20 11.51
Peers
Company Name CMP
Sun Pharma. Inds. 1868.00
Dr. Reddys Labs. 1202.00
Cipla 1385.00
Lupin 2120.00
Zydus Lifesciences 1161.50
View more..